H.C. Wainwright analyst Sara Nik has reiterated their bullish stance on MBRX stock, giving a Buy rating on May 13.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sara Nik has given his Buy rating due to a combination of factors that highlight Moleculin Biotech’s favorable risk‑reward profile and upcoming catalysts. The company’s Phase 2b/3 MIRACLE trial for Annamycin in relapsed/refractory AML is showing blinded composite remission and complete remission rates that materially exceed historical outcomes for cytarabine alone, suggesting meaningful differentiation if the effect is confirmed at unblinding.
The upcoming unblinding of the first 45 patients in 2Q26 should, for the first time, clarify dose‑response and separation versus the control arm, which could be a defining clinical inflection point. In addition, the ongoing enrollment pace toward completing Part A by 3Q26, together with the continued lack of cardiotoxicity seen with Annamycin, underpins confidence in both the safety profile and long‑term development path, supporting an unchanged $22 price target and a Buy recommendation.
Nik covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Curis, and Pasithea Therapeutics Corp. According to TipRanks, Nik has an average return of 8.8% and a 30.30% success rate on recommended stocks.
In another report released on May 13, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.